NEW YORK – Revolution Medicines can initiate an expanded access treatment protocol for its investigational RAS(ON) inhibitor daraxonrasib for pancreatic cancer, the US Food and Drug Administration ...

NEW YORK – The majority of experts on a US Food and Drug Administration advisory committee found that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation ...

NEW YORK – Amgen recorded double-digit growth for its KRAS inhibitor Lumakras (sotorasib) in the first quarter of 2025 but also announced it is discontinuing development of AMG 193, an MTA-cooperative ...

The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.

NEW YORK – The majority of experts on a US Food and Drug Administration advisory panel on Thursday remained unconvinced that there's sufficient evidence to support giving certain advanced breast ...

The firm, having run into roadblocks trying to bring AMT-130 to market in the US, said it is "actively pursuing" regulatory approvals internationally.

NEW YORK – Kestrel Therapeutics said today that it has signed an agreement with AbbVie under which AbbVie will fund the development of its KST-6051 pan-KRAS inhibitor in exchange for the exclusive ...

NEW YORK - The National MPS Society this week said it is awarding a $4 million grant to support a gene therapy program for mucopolysaccharidoses (MPS) IIIB (Sanfilippo syndrome type B) led by ...

NEW YORK – Merck expects its proposed acquisition of Terns Pharmaceuticals to strengthen and diversify its pipeline, which is staring down patent expirations for its top-selling product, the ...